Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene.

Wojas-Turek J, Pajtasz-Piasecka E, Rossowska J, Piasecki E, Duś D.

Folia Histochem Cytobiol. 2012 Oct 8;50(3):414-9. doi: 10.5603/19750.


Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.

Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A, Dus D.

Oncol Rep. 2007 May;17(5):1249-57.


Generation of antitumor response by IL-2-transduced JAWS II dendritic cells.

Rossowska J, Pajtasz-Piasecka E, Ryśnik O, Wojas J, Krawczenko A, Szyda A, Duś D.

Immunobiology. 2011 Oct;216(10):1074-84. doi: 10.1016/j.imbio.2011.05.006. Epub 2011 May 14.


Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.

Wojas-Turek J, Szczygieł A, Kicielińska J, Rossowska J, Piasecki E, Pajtasz-Piasecka E.

Int J Oncol. 2016 Feb;48(2):493-505. doi: 10.3892/ijo.2015.3278. Epub 2015 Dec 7.


Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number.

Rossowska J, Pajtasz-Piasecka E, Anger N, Wojas-Turek J, Kicielińska J, Piasecki E, Duś D.

J Immunother. 2014 Nov-Dec;37(9):427-39. doi: 10.1097/CJI.0000000000000054.


Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response.

Rossowska J, Pajtasz-Piasecka E, Szyda A, Zietara N, Duś D.

Folia Histochem Cytobiol. 2007;45(4):349-55.


The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.


Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.

Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):337-49.


Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.

Furumoto K, Arii S, Yamasaki S, Mizumoto M, Mori A, Inoue N, Isobe N, Imamura M.

Int J Cancer. 2000 Sep 1;87(5):665-72.


Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.

Rossowska J, Anger N, Kicielińska J, Pajtasz-Piasecka E, Bielawska-Pohl A, Wojas-Turek J, Duś D.

Immunobiology. 2015 Mar;220(3):389-98. doi: 10.1016/j.imbio.2014.10.009. Epub 2014 Oct 23.


Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo.

Rossowska J, Pajtasz-Piasecka E, Szyda A, Krawczenko A, Zietara N, Dus D.

Oncol Rep. 2009 Jun;21(6):1539-49.


Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.

Eguchi J, Hiroishi K, Ishii S, Mitamura K.

Cancer Immunol Immunother. 2003 Jun;52(6):378-86. Epub 2003 Mar 18.


Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.

Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X, Dai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H.

BMC Cancer. 2014 Jan 29;14:48. doi: 10.1186/1471-2407-14-48.


CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.

Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G, Colombo MP.

Eur J Immunol. 1995 Jan;25(1):137-46.


Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ, Yamaue H.

Int J Cancer. 2007 Feb 1;120(3):585-93.


Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.

Vo MC, Lee HJ, Kim JS, Hoang MD, Choi NR, Rhee JH, Lakshmanan VK, Shin SJ, Lee JJ.

Oncotarget. 2015 Oct 20;6(32):33781-90. doi: 10.18632/oncotarget.5281.


Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.

Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ.

J Surg Res. 2011 Jul;169(1):e43-50. doi: 10.1016/j.jss.2011.03.067. Epub 2011 Apr 21.


A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.

Jack AM, Aydin N, Montenegro G, Alam K, Wallack M.

J Surg Res. 2007 May 15;139(2):164-9. Epub 2007 Feb 1.


Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.

Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P.

Cancer Res. 2007 Oct 15;67(20):10012-8.

Supplemental Content

Support Center